Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration

Journal of Clinical Lipidology

Volumn 3, Issue 4, 2009, Pages 275-280

  Reddy, Kota J ^a   Singh, Manmeet ^a   Batsell, Richard R ^b   Bangit, Joey R ^a   Miraskar, Rekha A ^a   Zaheer, Misbah S ^a   Cockerham, Carol ^a   Wegner, Michael ^c  

^a Reddy Cardiac Wellness   (United States)

^b RICE UNIVERSITY   (United States)

^c diaDexus Inc   (United States)

Author keywords

Combination therapy; LDL C; Low carbohydrate diet; Low saturated fat diet; Lp PLA2; Niacin; Statin

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHOLESTEROL; COLESEVELAM; EZETIMIBE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PHOSPHOLIPASE A2; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIET THERAPY; DYSLIPIDEMIA; EXERCISE; FEMALE; HUMAN; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 68349105771     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.06.004     Document Type: Article

References (37)

1. Miniño A.M., Heron M.P., Murphy S.L., and Kochanek K.D. Deaths: final data for 2004. Natl Vital Stat Rep 55 (2007) 7
2. Kesteloot H., Sans S., and Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J 27 (2006) 107-113
3. Thom T., Haase N., Rosamond W., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
4. Rosamond W., Flegal K., Furie K., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117 (2008) e25-e146
5. National cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Third report of national cholesterol education program expert panel on Detection, Evaluation and treatment of high blood cholesterol in adults. Circulation 106 (2002) 3143-3421 II-30-II-31
6. Khot U.N., Khot M.B., Bajzer C.T., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290 (2003) 898-904
7. Garza C.A., Montori V.M., McConnell J.P., Somers V.K., Kullo I.J., and Lopez-Jimenz F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systemic review. Mayo Clin Proc 82 (2007) 159-165
8. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption (review). Circulation 92 (1995) 657-671
9. Häkkinen T., Luoma J.S., Hiltunen M.O., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 2909-2917
10. Kolodgie FD, Burke AP, Taye A. Lipoprotein -associated phospholipase a2 is highly expressed in macrophages of coronary lesions prone to rupture. Presented at the Annual scientific sessions of American Heart Association, 11 Nov 2004, New Orleans LO, USA.
11. MacPhee C.H., Moores K.E., Boyd H.F., et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 338 (1999) 479-487
12. Quinn M.T., Parthasarathy S., and Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A 85 (1988) 2805-2809
13. Elisaf M., and Tselepis A.D. Effect of hypolipidemic drugs on lipoprotein associated platelet activating factor acetlyhydrolase. Implication for atherosclerosis. Biochem Pharmacol 66 (2003) 2069-2073
14. Tambaki A.P., Rizos E., Tsimihodimos V., Tselepis A.D., and Elisaf M. Effect of antihypertensive and hypolipidemic drugs on plasma and HDL-associated PAF-acetylhydrolase activity. J Cardiovasc Pharmacol Ther 9 (2004) 91-95
15. Tsimihodimos V., Karabina S.A., Tambaki A.P., et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22 (2002) 306-311
16. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
17. Kudolo G.B., Bressler P., and DeFronzo R.A. Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment. J Lipid Mediat Cell Signal 17 (1997) 97-113
18. Zhang B., Fan P., Shimoji E., et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 186 (2006) 291-301
19. Winkler K., Abletshauser C., Friedrich I., Hoffmann M.M., Wieland H., and Marz W. Fluvastatin slow release lowers platelet activating factor acetyl hydrolase activity: a placebo controlled trial in patients with Type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 1153-1159
20. 2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
21. Saougos V.G., Tambaki A.P., Kalogirou M., et al. Differentials effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arteriosclerosis Thromb Vasc Biol 27 (2007) 2236-2243
22. Kuvin J.T., Dave D.M., Sliney K.A., et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 98 (2006) 743-745
23. Gaubatz J.W., Gillard B.K., Massey J.B., et al. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res 48 (2007) 348-357
24. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the investigation of treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
25. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid -lowering therapy on the characterstics of carotid atherosclerosis plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
26. Albert M.A., Glynn R.J., Wolfert R.L., and Ridker P.M. The effect of statin therapy on lipoprotein-associated phospholipase A2 levels. Atherosclerosis 182 (2005) 193-198
27. Muhulestein J.B., May H.T., Jensen J.R., et al. The reduction of inflammatory biomarkers by statin, fibrate and combination therapy among diabetic patients with mixed dyslipidemia. J Am Coll Cardiol 48 (2006) 396-401
28. Schaefer E.J., McNamara J.R., Asztalos B.F., et al. Effects of atrovastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95 (2005) 1025-1032
29. Zhang B., Fan P., Shimoji E., et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 186 (2006) 291-301
30. Shalwitz R.A., Maki K.V., Doyle R.T., and Ballantyne C.M. Lipoprotein subfraction responses differentially predict changes in lipoprotein-associated phospholipase A2 during prescription omega-3 therapy. Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference 27 (2007) e93-e94
31. O'Donoghue M., Morrow D.A., Sabatine M.S., et al. Lp-PlA2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE-IT-TIMI 22. Circulation 113 (2006) 1745-1752
32. Winkler K., Abletshauser C., Friedrich I., and Hoffman N.M. Wieland H, März W. Fluvstatin, slow- release lowers platlet-activating factors acetyl hydrolase activity; a placebo controlled trial in patients with type 2 diabetes. J Clin Endocrinol Metab 89 (2005) 1153-1159
33. Davidson M.H., Stein E.A., Bays H.E., et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 29 (2007) 1354-1367
34. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21 (2002) 495-505
35. Engler M.B. Vascular effects of omega-3 fatty acids: possible therapeutic mechanisms in cardiovascular disease. J Cardiovasc Nurs 8 (1994) 53-67
36. Babcock T.A., Dekoj T., and Espat N.J. Experimental studies defining omega-3 fatty acid antiinflammatory mechanisms and abrogation of tumor-related syndromes. Nutr Clin Pract 20 (2005) 62-74
37. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250